Decreased C-MYC and BCL2 expression correlates with methylprednisolone- mediated inhibition of Raji lymphoma growth

Geoffrey Morris, Sally J. Denardo, Gerald L Denardo, Tatiana Leshchinsky, Biao Wu, Philip Mack, Michelle D. Winthrop, Paul H. Gumerlock

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Methylprednisolone (MP) and related corticosteroids are a fundamental part of regimens used to treat lymphoma and leukemia. In many of these malignancies, oncogenic activation of C-MYC and BCL2 is seen. Abnormalities of the tumor suppressor p53, which exerts growth-suppressing and apoptosis- enhancing functions through the transcriptional regulation of downstream genes including CDKN1, GADD45, and BCL2, are also often found. The goal was to determine the modulation of expression of the oncogenes (C-MYC and BCL2), the p53 pathway described above, and the apoptosis marker TGF-β1 in the human Raji lymphoma following MP treatment. Raji xenografts were grown in nude mice and growth curves characterized by sequential measurement. Mice were treated daily for 8 days with MP. Tumors were harvested untreated, or at 1 or 8 days after cessation of MP treatment, and the RNA was extracted. RT- PCR was used to determine the level of mRNA expression of the genes. Tumor growth was greatly reduced in the MP-treated mice. Gene expression levels for C-MYC and BCL2 were reduced at 1 day following MP and approached control levels 8 days after MP treatment. Expression levels of p53, CDKN1, and GADD45 were moderately and coordinately decreased at 1 day after cessation of MP treatment and remained repressed a week later. TGF-β1 exhibited no change in expression levels. These results suggest that decreased expression of C- MYC and BCL2 may play a role in the molecular events that initiate and are responsible for the growth inhibition of Raji lymphoma xenografts by MP.

Original languageEnglish (US)
Pages (from-to)108-115
Number of pages8
JournalBiochemical and Molecular Medicine
Volume60
Issue number2
DOIs
StatePublished - Apr 1997

Fingerprint

Methylprednisolone
Lymphoma
Growth
Tumors
Withholding Treatment
Heterografts
Neoplasms
Genes
Apoptosis
Gene Expression
Level control
Oncogenes
Gene expression
Nude Mice
Adrenal Cortex Hormones
Leukemia
Chemical activation
Modulation
RNA
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Biochemistry

Cite this

Decreased C-MYC and BCL2 expression correlates with methylprednisolone- mediated inhibition of Raji lymphoma growth. / Morris, Geoffrey; Denardo, Sally J.; Denardo, Gerald L; Leshchinsky, Tatiana; Wu, Biao; Mack, Philip; Winthrop, Michelle D.; Gumerlock, Paul H.

In: Biochemical and Molecular Medicine, Vol. 60, No. 2, 04.1997, p. 108-115.

Research output: Contribution to journalArticle

Morris, Geoffrey ; Denardo, Sally J. ; Denardo, Gerald L ; Leshchinsky, Tatiana ; Wu, Biao ; Mack, Philip ; Winthrop, Michelle D. ; Gumerlock, Paul H. / Decreased C-MYC and BCL2 expression correlates with methylprednisolone- mediated inhibition of Raji lymphoma growth. In: Biochemical and Molecular Medicine. 1997 ; Vol. 60, No. 2. pp. 108-115.
@article{5cfdb2630b15458bbc60303a8baa9877,
title = "Decreased C-MYC and BCL2 expression correlates with methylprednisolone- mediated inhibition of Raji lymphoma growth",
abstract = "Methylprednisolone (MP) and related corticosteroids are a fundamental part of regimens used to treat lymphoma and leukemia. In many of these malignancies, oncogenic activation of C-MYC and BCL2 is seen. Abnormalities of the tumor suppressor p53, which exerts growth-suppressing and apoptosis- enhancing functions through the transcriptional regulation of downstream genes including CDKN1, GADD45, and BCL2, are also often found. The goal was to determine the modulation of expression of the oncogenes (C-MYC and BCL2), the p53 pathway described above, and the apoptosis marker TGF-β1 in the human Raji lymphoma following MP treatment. Raji xenografts were grown in nude mice and growth curves characterized by sequential measurement. Mice were treated daily for 8 days with MP. Tumors were harvested untreated, or at 1 or 8 days after cessation of MP treatment, and the RNA was extracted. RT- PCR was used to determine the level of mRNA expression of the genes. Tumor growth was greatly reduced in the MP-treated mice. Gene expression levels for C-MYC and BCL2 were reduced at 1 day following MP and approached control levels 8 days after MP treatment. Expression levels of p53, CDKN1, and GADD45 were moderately and coordinately decreased at 1 day after cessation of MP treatment and remained repressed a week later. TGF-β1 exhibited no change in expression levels. These results suggest that decreased expression of C- MYC and BCL2 may play a role in the molecular events that initiate and are responsible for the growth inhibition of Raji lymphoma xenografts by MP.",
author = "Geoffrey Morris and Denardo, {Sally J.} and Denardo, {Gerald L} and Tatiana Leshchinsky and Biao Wu and Philip Mack and Winthrop, {Michelle D.} and Gumerlock, {Paul H.}",
year = "1997",
month = "4",
doi = "10.1006/bmme.1997.2568",
language = "English (US)",
volume = "60",
pages = "108--115",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Decreased C-MYC and BCL2 expression correlates with methylprednisolone- mediated inhibition of Raji lymphoma growth

AU - Morris, Geoffrey

AU - Denardo, Sally J.

AU - Denardo, Gerald L

AU - Leshchinsky, Tatiana

AU - Wu, Biao

AU - Mack, Philip

AU - Winthrop, Michelle D.

AU - Gumerlock, Paul H.

PY - 1997/4

Y1 - 1997/4

N2 - Methylprednisolone (MP) and related corticosteroids are a fundamental part of regimens used to treat lymphoma and leukemia. In many of these malignancies, oncogenic activation of C-MYC and BCL2 is seen. Abnormalities of the tumor suppressor p53, which exerts growth-suppressing and apoptosis- enhancing functions through the transcriptional regulation of downstream genes including CDKN1, GADD45, and BCL2, are also often found. The goal was to determine the modulation of expression of the oncogenes (C-MYC and BCL2), the p53 pathway described above, and the apoptosis marker TGF-β1 in the human Raji lymphoma following MP treatment. Raji xenografts were grown in nude mice and growth curves characterized by sequential measurement. Mice were treated daily for 8 days with MP. Tumors were harvested untreated, or at 1 or 8 days after cessation of MP treatment, and the RNA was extracted. RT- PCR was used to determine the level of mRNA expression of the genes. Tumor growth was greatly reduced in the MP-treated mice. Gene expression levels for C-MYC and BCL2 were reduced at 1 day following MP and approached control levels 8 days after MP treatment. Expression levels of p53, CDKN1, and GADD45 were moderately and coordinately decreased at 1 day after cessation of MP treatment and remained repressed a week later. TGF-β1 exhibited no change in expression levels. These results suggest that decreased expression of C- MYC and BCL2 may play a role in the molecular events that initiate and are responsible for the growth inhibition of Raji lymphoma xenografts by MP.

AB - Methylprednisolone (MP) and related corticosteroids are a fundamental part of regimens used to treat lymphoma and leukemia. In many of these malignancies, oncogenic activation of C-MYC and BCL2 is seen. Abnormalities of the tumor suppressor p53, which exerts growth-suppressing and apoptosis- enhancing functions through the transcriptional regulation of downstream genes including CDKN1, GADD45, and BCL2, are also often found. The goal was to determine the modulation of expression of the oncogenes (C-MYC and BCL2), the p53 pathway described above, and the apoptosis marker TGF-β1 in the human Raji lymphoma following MP treatment. Raji xenografts were grown in nude mice and growth curves characterized by sequential measurement. Mice were treated daily for 8 days with MP. Tumors were harvested untreated, or at 1 or 8 days after cessation of MP treatment, and the RNA was extracted. RT- PCR was used to determine the level of mRNA expression of the genes. Tumor growth was greatly reduced in the MP-treated mice. Gene expression levels for C-MYC and BCL2 were reduced at 1 day following MP and approached control levels 8 days after MP treatment. Expression levels of p53, CDKN1, and GADD45 were moderately and coordinately decreased at 1 day after cessation of MP treatment and remained repressed a week later. TGF-β1 exhibited no change in expression levels. These results suggest that decreased expression of C- MYC and BCL2 may play a role in the molecular events that initiate and are responsible for the growth inhibition of Raji lymphoma xenografts by MP.

UR - http://www.scopus.com/inward/record.url?scp=0031128329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031128329&partnerID=8YFLogxK

U2 - 10.1006/bmme.1997.2568

DO - 10.1006/bmme.1997.2568

M3 - Article

C2 - 9169090

AN - SCOPUS:0031128329

VL - 60

SP - 108

EP - 115

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 2

ER -